Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Abelson (Abl) tyrosine kinase inhibition is a therapeutic focus for neurodegeneration.
• Elevated levels of Discoidin Domain Receptors (DDR1/2) tyrosine kinases are observed in Alzheimer's and Parkinson's disease brains.
• Knockdown of tyrosine kinases reduces neurotoxic proteins such as alpha-synuclein, beta-amyloid, and tau.

Purpose of the Study:

• To investigate the brain penetration and efficacy of multi-kinase inhibitors.
• To determine if therapeutic effects on neurotoxic proteins correlate with brain concentration or Abl selectivity.
• To explore potential co-targets with Abl for neurodegenerative pathologies.

Main Methods:

• Profiling pharmacokinetics of multi-kinase inhibitors (Nilotinib, Bosutinib, Bafetinib, Radotinib, LCB-03-0110).
• Assessing the ability of these agents to reduce neurotoxic proteins.
• Comparing the efficacy of selective Abl inhibitors versus multi-kinase inhibitors.

Main Results:

• Effective doses showed differential plasma:brain ratios, with Nilotinib at 1% and others ranging up to 12%.
• Multi-kinase inhibitors (Nilotinib, LCB-03-0110, Bosutinib) were more effective in reducing toxic proteins than selective Abl inhibitors.
• Therapeutic efficacy was independent of absolute brain concentration and Abl selectivity.

Conclusions:

• Targeting Abl in combination with other tyrosine kinases like DDRs and Src shows therapeutic potential for neurodegeneration.
• Multi-kinase inhibition may offer advantages over selective Abl inhibition for treating neurodegenerative diseases.
• DDRs and Src represent promising co-targets alongside Abl for neurodegenerative conditions.